Diabetes Virtual Camp

ADA Scholars - Standards of Care in Diabetes - Update for Early Career Professionals webinar
Standards of Care in Diabetes 2026 Update for Early Career Professionals
The 2026 Standards of Care in Diabetes includes the American Diabetes Association's (ADA) current clinical practice recommendations and is intended to provide clinicians, patients, researchers, payers, and others with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care. The recommendations are based on an extensive review of the clinical diabetes literature, supplemented with input from the ADA staff and the medical community at large. The Standards of Care in Diabetes is updated annually, or more frequently online if new evidence or regulatory changes merit immediate incorporation and is published in Diabetes Care. Join this session to hear first-hand updates to the 2026 Standards of Care guidelines from Rita R. Kalyani, MD, MHS.
Learn more and register. https://lnkd.in/eqHdRkfV
Date: Wednesday, March 4, 2026, at 11 am EST
Moderator: Daisy Duan, MD, Assistant Professor, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine
Presenter: Rita R. Kalyani, MD, MHS, Chief Scientific & Medical Officer, American Diabetes Association
Learning Objective: At the end of this activity, the attendees should be able to identify the 2026 ADA Standards of Care for classifying, diagnosing, preventing and treating prediabetes and diabetes.
Audience: This session is specifically intended for Early Career Health Care Professionals, Endocrine and Diabetes Fellows.
This webinar is supported in part by a restricted educational grant from the Leona M. and Harry B. Helmsley Charitable Trust and Corcept Therapeutics
Visit professional.diabetes.org/scholars to learn more about the ADA's Early Career program.

ADA Scholars Program 2025 | American Diabetes Association Apply for the ADA Scholars Program to advance your career in diabetes research and care. Networking, mentorship, and career workshops await!

August 15, 2025. Session 11. “Anti-Diabetic Effects of Estrogen and Testosterone in Women and Men” by Dr. Franck Mauvais-Jarvis (Tulane University School of Medicine). After 2 weeks of exciting and inspiring sessions from the Experts, we have reached the finale of this year’s program. Dr. Mauvais-Jarvis began by illustrating how s*x is a genetic modifier of human diseases. Estradiol and testosterone are key metabolic hormones in females, with estrogens playing a potent role in regulating insulin sensitivity and glucose homeostasis. Interestingly, all autoimmune disorders have a female bias in prevalence, except for type 1 diabetes, which may relate to estrogen’s protective effects on beta-cell function and survival in females. Estradiol was also shown to improve human islet engraftment and revascularization in insulin-deficient diabetic mice. Dr. Mauvais-Jarvis further discussed how estrogens promote degradation of misfolded proinsulin, thereby protecting insulin production and delaying diabetes. Targeting estrogen delivery selectively to the brain and beta-cells was achieved using GLP-1-E2 fusion peptides, conferring metabolic protection via GLP-1R and ERa. Dr. Mauvais-Jarvis also discussed polycystic o***y syndrome, a topic of high interest to our interns. He then discussed how testosterone is an anti-diabetic hormone in men, and the testicular-islet axis uses testosterone to enhance GLP-1 action. He further presented how a conditional loss of androgen receptor in beta-cells resulted in type 2 diabetes phenotypes in mice, implicating an important role of testosterone in beta-cells. Dihydrotestosterone was shown to increase GLP-1 action as the androgen receptor interacts with GLP-1 receptor, resulting in increased GLP-1-mediated insulin secretion by the beta-cells. Dr. Mauvais-Jarvis ended by discussing how s*x differences in human islet cell transcriptomes predominantly affect s*x chromosome genes. Very interesting science on our s*x hormones as they relate to diabetes!